Assignee
XSPRAY PHARMA AB
SE·19 granted patents·4 pending applications·29 citations·filing 2019–2025
Top patents by PatentIndex Score
23 records- 0198US11241419B2Pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2020·Granted Feb 8, 2022·7 cites·24 claims
- 0297US11517562B2Pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2022·Granted Dec 6, 2022·3 cites·30 claims
- 0397US11426391B2Pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2022·Granted Aug 30, 2022·3 cites·30 claims
- 0497US11376243B2Pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2022·Granted Jul 5, 2022·4 cites·30 claims
- 0596US10799459B1Rapidly disintegrating solid oral dosage forms containing dasatinibXSPRAY PHARMA AB·Filed 2019·Granted Oct 13, 2020·12 cites·21 claims
- 0694US12576071B2Pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2024·Granted Mar 17, 2026·0 cites·30 claims
- 0793US12144804B1Pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2024·Granted Nov 19, 2024·0 cites·30 claims
- 0893US2024398769A1Pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2024·Application pending·0 cites
- 0991US12076314B2Pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2024·Granted Sep 3, 2024·0 cites·30 claims
- 1083US12419892B2Pharmaceutical compositions comprising nilotinibXSPRAY PHARMA AB·Filed 2024·Granted Sep 23, 2025·0 cites·20 claims
- 1183US11963951B2Pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2021·Granted Apr 23, 2024·0 cites·23 claims
- 1282US11833249B2Rapidly disintegrating solid oral dosage forms containing dasatinibXSPRAY PHARMA AB·Filed 2022·Granted Dec 5, 2023·0 cites·12 claims
- 1376US11344500B2Rapidly disintegrating solid oral dosage forms containing dasatinibXSPRAY PHARMA AB·Filed 2020·Granted May 31, 2022·0 cites·22 claims
- 1475US10894018B1Rapidly disintegrating solid oral dosage forms containing dasatinibXSPRAY PHARMA AB·Filed 2020·Granted Jan 19, 2021·0 cites·20 claims
- 1575US10894017B1Rapidly disintegrating solid oral dosage forms containing dasatinibXSPRAY PHARMA AB·Filed 2020·Granted Jan 19, 2021·0 cites·20 claims
- 1675US10874614B1Rapidly disintegrating solid oral dosage forms containing dasatinibXSPRAY PHARMA AB·Filed 2020·Granted Dec 29, 2020·0 cites·20 claims
- 1775US10874613B1Rapidly disintegrating solid oral dosage forms containing dasatinibXSPRAY PHARMA AB·Filed 2020·Granted Dec 29, 2020·0 cites·20 claims
- 1875US10869837B1Rapidly disintegrating solid oral dosage forms containing dasatinibXSPRAY PHARMA AB·Filed 2020·Granted Dec 22, 2020·0 cites·20 claims
- 1975US10869836B1Rapidly disintegrating solid oral dosage forms containing dasatinibXSPRAY PHARMA AB·Filed 2020·Granted Dec 22, 2020·0 cites·20 claims
- 2074US2025375449A1Pharmaceutical compositions comprising nilotinibXSPRAY PHARMA AB·Filed 2025·Application pending·0 cites
- 2165US2024024248A1Fast dissolving pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2023·Application pending·0 cites
- 2262US2023121325A1Fast dissolving pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2022·Application pending·0 cites
- 2359US11529351B2Fast dissolving pharmaceutical compositionsXSPRAY PHARMA AB·Filed 2022·Granted Dec 20, 2022·0 cites·17 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →